## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: PEG 35.49 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.18)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 2, Bearish: 7)

**1. Baxter International (BAX) Is Up 7.5% After Class Action Over Infusion Pump Defects Filed**
- Source: Simply Wall Street | 20251216T113300 | Bearish | Relevance: 100%
- Baxter International is facing a class action lawsuit alleging it concealed defects in its Novum LVP infusion pumps and misled investors. This legal action significantly heightens the company's risks, potentially impacting regulatory scrutiny, customer confidence, and its financial flexibility amidst ongoing efforts to reshape its portfolio. Despite these challenges, Baxter's investment narrative projects substantial revenue and earnings growth by 2028, suggesting a potential upside to its current price according to some analyses.

**2. Baxter International (BAX) Is Up 7.5% After Class Action Over Infusion Pump Defects Filed**
- Source: Simply Wall Street | 20251216T110815 | Somewhat-Bearish | Relevance: 100%
- A class action lawsuit has been filed against Baxter International (BAX) by Levi & Korsinsky, LLP, alleging the company concealed serious safety defects in its Novum LVP infusion pumps between February 23, 2022, and October 29, 2025. The lawsuit highlights reported malfunctions, injuries, and deaths linked to the pumps, questioning Baxter's product oversight and investor disclosures. This legal action could significantly impact Baxter's investment narrative, particularly concerning regulatory scrutiny, customer confidence, and financial flexibility while it addresses other balance sheet constraints.

**3. BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit with the Schall Law Firm**
- Source: Business Wire | 20251215T170751 | Bearish | Relevance: 100%
- The Schall Law Firm is encouraging investors who purchased Baxter International Inc. (BAX) securities between February 23, 2022, and July 30, 2025, to join a class action lawsuit. This lawsuit alleges Baxter made false and misleading statements regarding widespread malfunctions of its Novum IQ Large Volume Pump, which exposed patients to serious risks. Investors who suffered losses are urged to contact the firm before December 15, 2025, to participate and potentially recover damages.

**4. BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care**
- Source: TradingView — Track All Markets | 20251215T150752 | Bullish | Relevance: 100%
- Baxter International Inc. (BAX) recently presented real-world data at the ASHP 2025 Midyear Clinical Meeting, showcasing the benefits of integrating smart infusion pumps with hospital EMRs. The data, gathered from over one million IV infusions using Baxter’s Spectrum IQ pumps, demonstrated reductions in patient safety alerts, shorter infusion programming times, and improved clinician productivity. These findings support the long-term growth of BAX by highlighting enhanced patient safety and nursing efficiency through connected infusion technologies.

**5. FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International**
- Source: Business Wire | 20251215T150745 | Bearish | Relevance: 100%
- Faruqi & Faruqi, LLP is investigating potential securities claims against Baxter International Inc. (NYSE: BAX) on behalf of investors who purchased securities between February 23, 2022, and October 29, 2025. The investigation focuses on allegations that Baxter made false or misleading statements regarding systemic defects in its Novum LVP medical devices, which exposed patients to serious risks and led to a significant stock drop. Investors have until December 15, 2025, to seek lead plaintiff status in the federal securities class action.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.5x requires aggressive growth execution.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Long-term trend broken: trading 26.7% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +5.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 35.49 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.9B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.49 |
| Forward P/E | 8.4 |
| Current P/E | 8.2 |
| YoY Growth | -2.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.5% to 5.8% (+5.3% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 79th percentile. MRS_5 at 2.5% confirms short-term momentum alignment. AM_20 at 3.7% shows strong absolute momentum above own 20MA. Outperforming sector by 4.1pp, stock-specific strength. Below SMA200 (0.73x), long-term trend not supportive. RSI neutral at 53. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.76% (CS: 79) | Strong |
| RSI_14 | 53.4 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 0.973x | Below |
| vs SMA200 | 0.733x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.30
- **Stop Loss:** $18.18 (5.8% risk)
- **Target:** $20.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 964
- **Position Value:** $18,605.20
- **Portfolio %:** 18.61%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*